On October 9th, Everest Medicines has successfully completed its listing on the main board of the HKEx, raising a total found of around HK$ 3.28 billion.

 

Goldman Sachs and BofA Securities acted as joint sponsors, joint global coordinators, joint bookrunners and joint lead managers of this offering.

 

Skadden, Arps, Slate, Meagher & Flom and affiliates, Zhong Lun Law Firm and Maples and Calder (Hong Kong) LLP acted as the legal advisors to the issuer on Hong Kong and United States laws, PRC law and Cayman Islands law respectively.

 

Kirkland & Ellis and Tian Yuan Law Firm acted as the legal advisors to the underwriters on Hong Kong and U.S. laws and PRC law respectively.

 

PricewaterhouseCoopers acted as the reporting accountant and auditor of the deal.

 

Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercializes potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.